Severe confusion, a seizure, slow or difficult breathing, collapse or immediate suicidal danger needs emergency assessment. Do not independently stop psychiatric or addiction medicines or attempt a home detox from alcohol or sedatives. All prescribing teams need the complete medicine and substance-use history.
When a mental-health condition and a substance-use disorder occur together, treatment should connect the two rather than split the person between competing plans. Medication may address depression, psychosis, bipolar disorder, opioid use disorder, alcohol dependence or several needs at once. That does not mean one medicine treats everything. A coherent plan explains the purpose of each prescription, its interaction risks, the monitoring and who is responsible for follow-up.
What co-occurring disorders means
Co-occurring disorders refers to the presence of a mental-health disorder and a substance-use disorder. The term does not identify one fixed combination or imply that one condition necessarily caused the other. SAMHSA recommends integrated assessment and treatment that considers the whole person, including physical and social needs. [1]
Examples can include depression with alcohol use disorder, PTSD with opioid use disorder or psychosis alongside problematic cannabis use. Each requires its own assessment. A label such as dual diagnosis should open a more complete discussion, not become a reason to assume every symptom is caused by drugs or that psychiatric treatment is irrelevant.
Distinguishing symptoms over time
Intoxication, withdrawal, sleep deprivation and medication effects can resemble or worsen psychiatric symptoms. A clinical timeline helps: which symptoms existed before substance use, which changed during periods of reduced use and which followed a prescription change? Previous records and observations from trusted supporters may be useful when shared with appropriate agreement.
This assessment can evolve as a person stabilizes. Uncertainty does not justify ignoring severe depression, mania, psychosis or immediate safety risks. Conversely, a symptom observed during withdrawal should not automatically be treated as proof of a permanent separate disorder. The team should explain what is known, what remains uncertain and what will be reassessed.
Start with immediate medical and psychiatric safety
Slow or absent breathing, collapse, seizures, severe confusion or immediate suicidal danger requires urgent care. Severe alcohol or sedative withdrawal can be medically dangerous and may need hospital-level management. The appropriate setting depends on current risks and clinical capabilities, not simply on whether a service calls itself residential treatment.
NICE’s guidance for psychosis with coexisting substance misuse recommends specialist involvement and an inpatient setting for planned detoxification in that specific population. This should not be generalized into a rule for every person with a co-occurring diagnosis, but it illustrates why assessment and setting matter. Withdrawal management belongs within an overall treatment plan. [2]
Build one accurate medication and substance-use record
List prescribed medicines, actual doses and timing, missed doses, nonprescribed medicines, alcohol, recreational substances and supplements. Include products used occasionally for sleep, pain, concentration or weight control. The distinction between intended and actual use is essential: a list copied from the prescription may not explain the symptoms a person is experiencing.
Explain what each substance is used to manage. Someone may take a sedative to offset a stimulant, drink to reduce social anxiety or use an opioid for emotional relief as well as pain. These patterns affect treatment and interactions. They should be discussed without moral judgment so that the team can make a safer plan.
Psychiatric medicines retain condition-specific roles
An antidepressant may treat depression or an anxiety-related disorder, but it is not automatically treatment for alcohol or opioid use disorder. Mood stabilizers and antipsychotics also have specific roles according to the condition, episode and product. The plan should identify the target symptoms and expected benefit instead of treating every medicine as a general tool for stabilization.
For psychosis with coexisting substance misuse, NICE advises choosing antipsychotics according to the relevant psychiatric guidelines rather than assuming one agent has a special overall advantage because substance use is present. Long-acting injections may address a specific adherence need, but they are not a universal treatment for the combined diagnosis. [2]
Alcohol treatment: withdrawal and relapse prevention differ
A short-term medicine used in medically supervised alcohol withdrawal serves a different purpose from ongoing treatment intended to support reduced drinking or abstinence. The alcohol medication guide explains the roles of medicines such as acamprosate, naltrexone and disulfiram alongside assessment and psychosocial care.
Ask which stage of treatment each medicine belongs to and what will happen when that stage ends. Continuing a sedative indefinitely because it helped during withdrawal may create a new dependence problem. Equally, a relapse-prevention prescription does not make it safe to attempt an unsupervised withdrawal when severe physical dependence is present.
Opioid use disorder needs its own evidence-based treatment
Buprenorphine, methadone and naltrexone have different roles in opioid-use-disorder treatment. CDC advises against detoxification alone without ongoing medication because of the risk of returning to use and overdose. Psychiatric treatment should be coordinated with this care rather than used as a substitute for it. [3]
Starting requirements and pain-treatment implications differ. Naltrexone can precipitate withdrawal in a person with opioid dependence, and buprenorphine initiation also needs a specific plan. A person should not choose a medicine from an online comparison and start it using another patient’s instructions. The opioid-treatment hub explains these distinctions.
Sedating combinations require coordination, not abandonment of care
Alcohol, benzodiazepines, opioids and other sedating medicines can combine to increase respiratory and cognitive risks. Each prescriber needs to know what the other teams supply. Marked drowsiness, confusion or slowed breathing should not be dismissed as a normal part of treatment.
FDA has cautioned against automatically withholding buprenorphine or methadone solely because benzodiazepines or other central nervous system depressants are involved; untreated opioid addiction can cause greater harm. The response is careful assessment, monitoring and coordinated management, not abrupt self-directed discontinuation or an assumption that the combination is harmless. [4]
PTSD treatment should not disappear behind the addiction diagnosis
VA guidance supports evidence-based trauma-focused treatment for people with both PTSD and substance-use disorders. Treatment may be concurrent or integrated according to the clinical situation. Substance use alone should not become a blanket reason to withhold appropriate PTSD care. Immediate withdrawal or safety needs may still require attention first. [5]
A medicine used briefly for withdrawal is not necessarily suitable for continuing PTSD symptoms. The PTSD medication guide separates core treatment from nightmare-focused prescribing and explains concerns about routine benzodiazepine use. Ask how trauma therapy and medication review will remain connected after acute stabilization.
Smoking, physical illness and medication exposure
Changing smoking can alter the exposure to some psychiatric medicines, including clozapine and olanzapine. A move to a smoke-free setting therefore needs a medication review even when no new psychiatric drug is started. Nicotine replacement does not simply reproduce every metabolic effect of tobacco smoke.
Kidney or liver illness, dehydration, infections and nutritional problems can also change the safety of a prescription. The review should specify which physical measures or tests matter for the actual medicines. A normal result in one area does not replace assessment elsewhere. For example, a symptom that raises concern about lithium toxicity needs urgent action rather than routine reassurance.
Monitoring should include benefit as well as risk
Agree on a few meaningful outcomes for each treatment. These might include reduced cravings, fewer episodes of psychosis, improved sleep without excessive sedation, more reliable daily functioning or better participation in therapy. Record adverse effects at the same time so that a quiet presentation is not mistaken for recovery when the person is overly sedated.
Monitoring can include symptoms, physical observations, laboratory tests and discussion of substance use, depending on the plan. Explain the purpose of any testing and how results will be used. A finding should lead to assessment and appropriate support, not an automatic assumption that the person has failed treatment or should lose all care.
One coordinator and clear prescribing responsibilities
Integrated care can be delivered by a single team or by services that work together. SAMHSA describes coordinated, co-located and integrated models; sharing a building alone does not establish that prescriptions and treatment goals are being coordinated. Ask who holds the complete plan and who can resolve conflicting instructions. [6]
For people with psychosis and substance-related needs, NICE emphasizes a care coordinator when several professionals are involved. The person receiving treatment should be included in decisions and know who monitors physical health, who changes medication and whom to contact between appointments. Written responsibilities reduce the risk of important issues falling between services. [7]
Stopping medicines and responding to setbacks
Withdrawal from a psychiatric medicine can overlap with a return of the original condition or a change in substance use. Review the timeline and actual use rather than repeatedly stopping and restarting prescriptions to test the cause. Benzodiazepines and certain other medicines have particularly important stopping risks; a single generic taper is not appropriate for all treatments.
A return to substance use should trigger a safety and treatment review, including overdose risk, interactions and what made the plan difficult. It should not automatically erase previous progress. Similarly, a worsening psychiatric symptom should lead to assessment rather than an assumption that substance use is always the explanation. The aim is to adjust care using the full picture.
Handover, discharge and overdose prevention
Before leaving hospital or residential care, confirm the next appointments, exact medicines, supply, dispensing arrangements and contact for interruptions. Include plans for smoking changes, pain treatment and any pregnancy-related care. A discharge summary should explain why each medicine is used, not simply list names and amounts.
Where opioid risk is present, discuss access to naloxone and teach supporters how to use the actual device. Loss of tolerance after reduced use can make a return to previous patterns dangerous. Psychological, housing, social and practical support should also continue; medication access should not depend on every other service already being available. [3]
Frequently asked questions
Must one condition always be treated before the other?
No. The sequence depends on immediate safety, severity and the treatment context. Acute medical needs may take priority, but ongoing mental-health and addiction care should be coordinated rather than separated by a blanket rule.
Can one medicine treat all co-occurring problems?
Usually that is not a useful assumption. Each prescription should have a defined purpose, evidence and review plan. Some medicines have more than one indication, but that does not make them universal treatments.
Does prescribed dependence mean treatment is wrong?
Physical dependence is not the same as addiction or treatment failure. The benefit, harms, pattern of use and alternatives need assessment. Abruptly stopping effective treatment can itself create risk.
What information is most useful at review?
Bring the actual medicine and substance-use pattern, recent changes, symptoms, practical barriers and your priorities. The medication-review checklist can help make the conversation clear without delaying urgent care.
